Will Alnylam’s New Five‑Year Roadmap and Early 2025 Revenue Update Redefine Its GARP Story (ALNY)?

Simply Wall St.01-11

Alnylam Pharmaceuticals recently outlined plans, now in the past, to present a company overview, early 2025 revenue figures, and a new five-year strategy at the 44th Annual J.P. Morgan Healthcare ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2602525305?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-01-11 22:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602525305","market":"nz","top_or_hot":-1,"title":"Will Alnylam’s New Five‑Year Roadmap and Early 2025 Revenue Update Redefine Its GARP Story (ALNY)?","media":"Simply Wall St.","content":"<div>\n<p>Alnylam Pharmaceuticals recently outlined plans, now in the past, to present a company overview, early 2025 revenue figures, and a new five-year strategy at the 44th Annual J.P. Morgan Healthcare ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alny/alnylam-pharmaceuticals/news/will-alnylams-new-fiveyear-roadmap-and-early-2025-revenue-up\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Will Alnylam’s New Five‑Year Roadmap and Early 2025 Revenue Update Redefine Its GARP Story (ALNY)?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWill Alnylam’s New Five‑Year Roadmap and Early 2025 Revenue Update Redefine Its GARP Story (ALNY)?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-11 22:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alny/alnylam-pharmaceuticals/news/will-alnylams-new-fiveyear-roadmap-and-early-2025-revenue-up><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Alnylam Pharmaceuticals recently outlined plans, now in the past, to present a company overview, early 2025 revenue figures, and a new five-year strategy at the 44th Annual J.P. Morgan Healthcare ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alny/alnylam-pharmaceuticals/news/will-alnylams-new-fiveyear-roadmap-and-early-2025-revenue-up\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GARP","symbol_name":"ISHARES MSCI USA QUALITY GARP ETF","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alny/alnylam-pharmaceuticals/news/will-alnylams-new-fiveyear-roadmap-and-early-2025-revenue-up","article_id":"2602525305","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alny/alnylam-pharmaceuticals/news/will-alnylams-new-fiveyear-roadmap-and-early-2025-revenue-up","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2602525305","pubTimestamp":1768140968,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Alnylam Pharmaceuticals recently outlined plans, now in the past, to present a company overview, early 2025 revenue figures, and a new five-year strategy at the 44th Annual J.P. Morgan Healthcare Conference, including an outlook for 2026 product sales via a live webcast.\nThis update comes as the company is viewed as financially disciplined with net cash, strong free cash flow conversion from EBIT, and interest in its growth-at-a-reasonable-price profile.\nWe’ll now examine how anticipation...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"GARP":"ISHARES MSCI USA QUALITY GARP ETF","ALNY":"阿尔尼拉姆制药公司"},"translate_title":"Alnylam的新五年路线图和2025年初收入更新是否会重新定义其GARP故事(ALNY)？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GARP":1.5,"ALNY":1.5},"content_text":"Alnylam Pharmaceuticals recently outlined plans, now in the past, to present a company overview, early 2025 revenue figures, and a new five-year strategy at the 44th Annual J.P. Morgan Healthcare Conference, including an outlook for 2026 product sales via a live webcast. This update comes as the company is viewed as financially disciplined with net cash, strong free cash flow conversion from EBIT, and interest in its growth-at-a-reasonable-price profile. We’ll now examine how anticipation around Alnylam’s five-year strategy unveiling and preliminary 2025 revenue update could influence its investment narrative. Outshine the giants: these 28 early-stage AI stocks could fund your retirement.AdvertisementAlnylam Pharmaceuticals Investment Narrative RecapTo own Alnylam, you need to believe its RNAi platform can keep translating into durable products while the company manages pricing pressure, spending, and TTR concentration risk. The J.P. Morgan update on preliminary 2025 revenues and a five year plan may shape sentiment around near term product sales, but it does not fundamentally change the biggest current swing factors: execution on AMVUTTRA pricing and margins, and whether high R&D and SG&A outlays stay aligned with future revenue potential. The most relevant recent announcement here is Alnylam’s plan to present a new five year strategy alongside unaudited 2025 net product revenues and a 2026 sales outlook at the J.P. Morgan Healthcare Conference. That disclosure gives investors a near term check point on how management prioritizes capital allocation and pipeline investment, which directly connects to the key catalyst of sustaining profitable growth without letting operating costs outpace the top line. Yet behind the upbeat framing, investors should be aware that sustained high R&D and SG&A spending could... Read the full narrative on Alnylam Pharmaceuticals (it's free!)Alnylam Pharmaceuticals' narrative projects $7.0 billion revenue and $1.9 billion earnings by 2028. This requires 41.8% yearly revenue growth and roughly a $2.2 billion earnings increase from -$319.1 million today.Uncover how Alnylam Pharmaceuticals' forecasts yield a $491.92 fair value, a 24% upside to its current price.Exploring Other PerspectivesALNY 1-Year Stock Price Chart Five fair value estimates from the Simply Wall St Community span roughly US$316 to US$847 per share, showing how far apart individual views on Alnylam’s potential can be. When you compare that spread with the upcoming five year strategy and 2025 revenue update, it underlines why many market participants are watching how management balances growth ambitions with tight control of operating costs.Explore 5 other fair value estimates on Alnylam Pharmaceuticals - why the stock might be worth over 2x more than the current price!Build Your Own Alnylam Pharmaceuticals NarrativeDisagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.A great starting point for your Alnylam Pharmaceuticals research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.Our free Alnylam Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Alnylam Pharmaceuticals' overall financial health at a glance.Ready To Venture Into Other Investment Styles?Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.AI is about to change healthcare. These 30 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.These 18 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2602525305","isCrawlerRequest":true}